uridine diphosphate glucose

Uridine diphosphate glucose is an important intermediate in several different metabolic pathways and biosynthetic reactions.

Dapagliflozin-3-O-β-D-glucuronide is a metabolite of dapagliflozin . Dapagliflozin is a first generation selective sodium glucose cotransporter (SGLT) 2 inhibitor that blocks glucose transport.[1] Dapagliflozin is metabolized by uridine diphosphate glucuronosyltransferase (UGT) 1A9 to dapagliflozin-3-O-β-D-glucuronide, which is 2,600-fold less potent than the parent compound with regard to SGLT2 inhibition.[2]

yGsy2p-IN-H23 is a potent, first-in-class inhibitor specifically designed to target yeast glycogen synthase 2 (yGsy2p). It demonstrates an IC50 value of 875 μM for human glycogen synthase 1 (hGYS1). This compound binds precisely within the uridine diphosphate glucose (UDPG) binding pocket of yGsy2p. Its utilization in research primarily focuses on studying glycogen storage diseases (GSDs).

Uridine diphosphate glucuronic acid (UDP-GlcA) trisodium 是一种在 UDP-葡萄糖脱氢酶催化过程中形成的辅助因子。它含有 Azide 基团，能够与含有 Alkyne 基团的分子进行铜催化的叠氮-炔环加成反应（CuAAc）。此外，它也可以与具有 DBCO 或 BCN 基团的分子进行环张力促进的炔-叠氮环加成反应 (SPAAC)。